ClinicalTrials.gg
TerminatedNCT00280085Updated Aug 7, 2009

The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

An interventional study of MR imaging and Glucose clamp in Diabetes Mellitus, sponsored by Pfizer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-07.

Sponsored by Pfizer · Not applicable, Interventional, and Diagnostic

Why this study was terminated
Explanation provided in detailed descriptiong section of record.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Diabetes Mellitus by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus · Pfizer.

Enrollment
23rd of 30
29 · median 182
Started
2005
with 2 others
No phase
Only one
of the 35
Registered
10th of 35
by date

Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 23rd largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is the only one with no phase, and was the 10th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 35 studies in Diabetes Mellitus by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Diabetes Mellitus by Pfizer, or all of them as a file.
02

Study summary

Assess pancreatic beta cell function using MR imaging.

Read the detailed description

The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal Volunteers
  • T1DM and T2DM subjects

Exclusion criteria

Exclusion Criteria:

  • Concomitant severe conditions
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Interventions

  • ProcedureMR imaging
  • ProcedureGlucose clamp
  • Also known as: R-Gene 10

06

What researchers measure

Primary outcomes

  1. Pancreatic perfusion

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06510, United States
08

References and documents

Publications

  • Hirshberg B, Qiu M, Cali AM, Sherwin R, Constable T, Calle RA, Tal MG. Pancreatic perfusion of healthy individuals and type 1 diabetic patients as assessed by magnetic resonance perfusion imaging. Diabetologia. 2009 Aug;52(8):1561-5. doi: 10.1007/s00125-009-1406-8. Epub 2009 Jun 3. PubMed 19488737 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2006
First posted
Jan 20, 2006
Start
Dec 2005
CompletionActual
Jul 2007
Last update
Aug 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00280085
Lead sponsor
Pfizer
Collaborators
Yale University
First posted
Jan 20, 2006
Start date
Dec 2005
Completion
Jul 2007
Last update
Aug 7, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion